(BPT) – Do you live with persistent, moderate-to-severe asthma, COPD, allergies, eczema or hives? Inflammation is often a major factor in the severity of your symptoms. It could also be a factor if ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel therapies for inflammation and immune diseases, announced today the discovery of potent, selective oral small ...

Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham, talks about a new trial in which dupilumab was used in patients with chronic obstructive pulmonary disease ...

Applications must pertain to Type 2 immunity or diseases characterized by Type 2 inflammation, including but not limited to: atopic dermatitis or eczema, chronic urticaria, allergic contact dermatitis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Dupilumab for uncontrolled asthma improved mucus ...

Patients with respiratory allergies and allergic asthma, which are characterized by chronic type 2 airway inflammation, are often less susceptible to severe COVID-19. Lower viral replication is ...

Meteorin-like protein (Metrnl) is an emerging secreted factor with a multifaceted role in regulating metabolism and modulating inflammatory responses. Initially identified as an adipomyokine, Metrnl ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 52 weeks, patients receiving dupilumab vs. placebo ...

A team sheds new light on the role of marine-source omega-3 supplementation in treating adipose tissue inflammation and reducing the risk for cardiometabolic diseases like type 2 diabetes. Published ...